Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabDrug: carmustineDrug: cytarabineDrug: etoposideDrug: melphalanProcedure: ASCTRadiation: yttrium Y 90 ibritumomab tiuxetan
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 122
- Registration Number
- NCT00695409
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
- Conditions
- Myelodysplastic/Myeloproliferative NeoplasmsLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmChronic Myeloproliferative DisordersMyelodysplastic Syndromes
- Interventions
- Biological: rituximabDrug: busulfanDrug: carmustineDrug: cyclophosphamideDrug: cytarabineDrug: etoposideDrug: fludarabine phosphateDrug: melphalanRadiation: total body irradiation (TBI)Drug: anti-thymocyte globulin IV
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT00691015
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabBiological: filgrastimBiological: bleomycin sulfateDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoloneDrug: vincristine sulfateDrug: etoposide phosphateDrug: methotrexateDrug: cytarabineDrug: ifosfamideDrug: prednisoneDrug: vindesine
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2009-07-08
- Target Recruit Count
- 120
- Registration Number
- NCT00689845
- Locations
- 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
🇬🇧Southampton General Hospital, Southampton, England, United Kingdom
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 220
- Registration Number
- NCT00671658
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia
- Interventions
- Drug: Calaspargase Pegol-mknlDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneRadiation: Radiation TherapyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 166
- Registration Number
- NCT00671034
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸University of Connecticut, Farmington, Connecticut, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
- Conditions
- LymphomaSmall Intestine Cancer
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 60
- Registration Number
- NCT00669812
- Locations
- 🇬🇧
Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
- Conditions
- Burkitt's LymphomaBurkitt'S-like Lymphoma
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT00669877
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myelomonocytic Leukemia (M4)Childhood Acute Eosinophilic LeukemiaChildhood Acute Erythroleukemia (M6)
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00666588
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 106
- Registration Number
- NCT00656617
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 717
- Registration Number
- NCT00651261
- Locations
- 🇺🇸
St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸Ministry Saint Clare's Hospital, Weston, Wisconsin, United States
🇺🇸Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.